Zeria USA to Bring Joint Health Ingredients to American Markets

Zeria USA, Inc. announced that ZPD’s pharmaceutical grade bulk sodium chondroitin sulfate is now available for North and South American markets. Zeria’s bulk chondroitin sulfate is produced at its Danish plant, ZPD A/S. Chondroitin sulfate, which is used in joint health formulations, is sold as a dietary supplement in the United States and as an over-the-counter drug in other countries.

"With aging global populations, demand for products with proven efficacy in the joint health category has spiked. Consumers are looking for proven safe and effective remedies. Our product meets the needs of global consumers and has been the best-selling consumer brand in Japan for more than 50 years," said Kohei Morooka, regional sales manager, Zeria USA, Inc.

Zeria USA, Inc., located in White Plains, New York, is responsible for the distribution of chondroitin sulfate manufactured by ZPD A/S for clients in North and South America. Zeria USA was established in 1989 and is a wholly owned subsidiary of Zeria Pharmaceutical Co., Ltd., headquartered in Tokyo.